Immunotherapy combo increases progression-free survival in advanced melanoma patients

31 mayo 2015

Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab and ipilimumab or nivolumab alone significantly increases progression-free survival over using ipilimumab alone, according to researchers.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/1gW8cKPhq20/150531100051.htm

Volver